靶向治疗高危胃肠道间质瘤的临床疗效
作者: |
1闵凯,
1曹峰瑜,
1任骏,
1吴彪,
1肖新波
1 湖北省武汉市第一医院 胃肠外科二,湖北 武汉 430022 |
通讯: |
曹峰瑜
Email: 915766973@qq.com |
DOI: | 10.3978/.10.3978/j.issn.1005-6947.2016.10.007 |
摘要
目的:探讨应用伊马替尼治疗高危胃肠道间质瘤(GIST)的临床疗效。方法:回顾性分析2010年1月—2015年6月收治的56例接受伊马替尼靶向治疗的高危GIST患者临床资料,并对疗效进行分析。结果:19例无手术切除机会的患者经伊马替尼(400 mg/d)治疗6~8个月后,无完全缓解(CR)者,部分缓解(PR)14例,疾病稳定(SD)4例,疾病进展(PD)1例;7例(36.8%)PR患者获得手术切除机会。35例行手术切除后服用伊马替尼(400 mg/d)1年,随访3例复发,1年复发率8.6%;2例终断服药,无法评估疗效。结论:伊马替尼治疗GIST疗效肯定,对于高危GIST患者,术前新辅助化疗能让无法手术切除的肿瘤获得手术机会,术后辅助化疗可能提高无瘤生存率,不良反应较轻能够耐受。
关键词:
胃肠道间质肿瘤
原癌基因蛋白质类c-kit
蛋白激酶抑制剂
分子靶向治疗
Clinical effect of imatinib targeted therapy on high risk gastrointestinal stromal tumor
CorrespondingAuthor:CAO Fengyu Email: 915766973@qq.com
Abstract
Objective: To explore the clinical effect of imatinib targeted therapy on high risk gastrointestinal stromal tumor (GISTS). Methods: The clinical data of 56 patients with high risk GIST undergoing imatinib targeted therapy from January 2010 to June 2015 were reviewed, and the therapeutic efficacy was analyzed. Results: Nineteen patients, who had no chance of surgical resection, received imatinib (400 mg/d) therapy for 6 to 8 months, and of them, none achieved complete response (CR), 14 cases obtained partial response (PR), 4 cases had stable disease (SD), and one case presented progressive disease (PD); 7 PR cases (36.8%) obtained a chance for tumor resection. Thirty-five patients received imtinib (400 mg/d) treatment for one year after surgical resection, and of them, recurrence occurred in 3 cases (8.6%) during follow-up and the one-year recurrence rate was 8.6%; 2 cases did not continue to take the medication and their results could not be determined. Conclusion: Imatinib has significant efficacy in GIST patients, and in those with high risk GIST, its preoperative neoadjuvant chemotherapy may offer a chance of surgical resection for the unresectable tumors, and its postoperative adjuvant chemotherapy may improve the tumor-free survival with tolerable adverse effects.
Keywords: